Galcanezumab: First Global Approval

@article{Lamb2018GalcanezumabFG,
  title={Galcanezumab: First Global Approval},
  author={Yvette N. Lamb},
  journal={Drugs},
  year={2018},
  volume={78},
  pages={1769-1775}
}
  • Yvette N. Lamb
  • Published 2018
  • Medicine
  • Drugs
  • Galcanezumab-gnlm (Emgality™; Eli Lilly and Company), hereafter galcanezumab, is a humanized monoclonal antibody against the calcitonin gene-related peptide (CGRP) ligand. A potent vasodilator, CGRP is implicated in nociceptive transmission and migraine pathogenesis. In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults. In the same month, the EMA issued a positive opinion for galcanezumab for the… CONTINUE READING
    12 Citations
    Monoclonal antibodies for the prevention of migraine
    • 11
    Soluble ligands as drug targets
    • PDF
    Emerging treatments for cluster headache: hopes and disappointments
    • D. Magis
    • Medicine
    • Current opinion in neurology
    • 2019
    • 1
    Was kann die Antikörpertherapie in der Neurologie?

    References

    SHOWING 1-10 OF 28 REFERENCES
    Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial
    • 87
    • PDF
    Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial
    • 181
    • Highly Influential
    • PDF
    Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
    • 162
    • Highly Influential
    • PDF
    Targeting CGRP: A New Era for Migraine Treatment
    • 56
    • PDF
    Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
    • 38
    Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
    • 39
    • PDF
    Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.
    • 63
    • Highly Influential
    EMGALITY (galcanezumab-gnlm) injection, for subcutaneous use: US prescribing information. 2018
    • http://pi.lilly .com/. Accessed
    • 2018